Published in Eur J Pharmacol on February 03, 2007
Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A (2012) 1.97
Benzbromarone stabilizes ΔF508 CFTR at the cell surface. Biochemistry (2011) 0.80
Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. J Pharmacol Clin Toxicol (2013) 0.77
Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science (1991) 5.82
The human ATP-binding cassette (ABC) transporter superfamily. Genome Res (2001) 5.47
Structure and function of the CFTR chloride channel. Physiol Rev (1999) 4.82
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev (2003) 3.69
The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci (1992) 3.22
Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol (2004) 3.10
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem (1994) 2.82
Pharmacology of CFTR chloride channel activity. Physiol Rev (1999) 2.41
The MRP family of drug efflux pumps. Oncogene (2003) 2.37
Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res (1994) 2.20
Structure and mechanism of ABC transporters. Curr Opin Struct Biol (2002) 1.84
ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res (1994) 1.73
Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res (1996) 1.69
Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology (2001) 1.66
Molecular pharmacology of the CFTR Cl- channel. Trends Pharmacol Sci (1999) 1.64
Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta (1999) 1.62
CFTR: mechanism of anion conduction. Physiol Rev (1999) 1.55
Glutathione permeability of CFTR. Am J Physiol (1998) 1.48
CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des (2006) 1.30
MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr (2001) 1.24
T84 cells: anion selectivity demonstrates expression of Cl- conductance affected in cystic fibrosis. Am J Physiol (1992) 0.98
Substrates of multidrug resistance-associated proteins block the cystic fibrosis transmembrane conductance regulator chloride channel. Br J Pharmacol (1999) 0.95
Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol Pharmacol (2004) 0.90
A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. J Pharm Pharmacol (2004) 0.85
TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science (2008) 8.74
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest (2002) 4.97
Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest (2005) 4.19
Chloride channels as drug targets. Nat Rev Drug Discov (2008) 3.22
Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol (2004) 3.10
Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem (2003) 2.25
Regulation of TMEM16A chloride channel properties by alternative splicing. J Biol Chem (2009) 2.16
High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem (2002) 1.89
Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. Am J Physiol Lung Cell Mol Physiol (2005) 1.87
Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol (2005) 1.80
Structure and function of TMEM16 proteins (anoctamins). Physiol Rev (2014) 1.56
TMEM16A protein: a new identity for Ca(2+)-dependent Cl⁻ channels. Physiology (Bethesda) (2010) 1.45
Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways. Am J Respir Crit Care Med (2005) 1.45
Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis. Biochem J (2008) 1.44
Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology (2007) 1.42
Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels. J Immunol (2007) 1.35
Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett (2004) 1.35
CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des (2006) 1.30
Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol (2010) 1.28
Altered expression of Ano1 variants in human diabetic gastroparesis. J Biol Chem (2011) 1.19
IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. J Immunol (2002) 1.18
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des (2010) 1.17
Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem (2004) 1.16
Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest (2012) 1.15
The anoctamin family: TMEM16A and TMEM16B as calcium-activated chloride channels. Exp Physiol (2011) 1.11
CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor. Am J Physiol Lung Cell Mol Physiol (2004) 1.11
Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides. Chem Biol (2008) 1.09
Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol (2012) 1.09
A minimal isoform of the TMEM16A protein associated with chloride channel activity. Biochim Biophys Acta (2011) 1.08
Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol Biol Cell (2012) 1.07
Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol (2002) 1.05
CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol (2003) 1.03
Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol (2007) 1.00
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol (2011) 0.98
A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett (2005) 0.97
Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem (2011) 0.97
TMEM16A-TMEM16B chimaeras to investigate the structure-function relationship of calcium-activated chloride channels. Biochem J (2013) 0.97
Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol (2005) 0.95
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res (2009) 0.95
Effect of inflammatory stimuli on airway ion transport. Proc Am Thorac Soc (2004) 0.94
Pharmacological therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros (2011) 0.93
Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem (2003) 0.92
Cystic fibrosis: a new target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines. J Med Chem (2011) 0.92
Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier. PLoS Genet (2010) 0.91
Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators. Interaction between activation and inhibition. J Biol Chem (2007) 0.90
Non-canonical translation start sites in the TMEM16A chloride channel. Biochim Biophys Acta (2013) 0.90
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One (2009) 0.89
A novel missense mutation in ANO5/TMEM16E is causative for gnathodiaphyseal dyplasia in a large Italian pedigree. Eur J Hum Genet (2012) 0.89